RAPP

Rating neutralAI Memo

Rapport Therapeutics

As of 2026-10-22/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FDA discussion of bipolar-mania registrational design • 2027-03-31

Base target: $28 / p=45% prob

Biggest risk

The bipolar-mania primary-endpoint p-value was 0.045, and treatment discontinuation was 24.6% on RAP-219 versus 11.8% on placebo. Replication, trial design and enrollment remain material risks; the company had no approved product in the cited operating update [#8-K-2026-10-20] [#SEC-8K-2026-08-05].

Invalidation

Break below $15 or thesis failure.

What would change my mind?

The October 20 placebo-controlled bipolar-mania Phase 2 result adds a second potential indication to an already enrolling focal-onset-seizure Phase 3 program. Rapport reported $436.1 million of cash, equivalents and short-term investments at June 30, 2026 and expected funding into H2 2029 [#8-K-2026-10-20] [#SEC-8K-2026-08-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-22

Base target

$28

p=45%

Bull target

$42

p=30%

Bear target

$15

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Focal-onset-seizure extension safety data
Broader RAP-219 epilepsy development
Bipolar-mania Phase 3 initiation

BearKey bullets

FDA feedback could require changes to the proposed bipolar-mania registrational program or delay its planned H2 2027 start [#8-K-2026-10-20].
Multiple planned Phase 3 studies may raise R&D spending and operational complexity; the H2 2029 runway is a company expectation based on June 30, 2026 liquidity, not a financing guarantee [#8-K-2026-10-20].
Overall treatment discontinuation was 24.6% for RAP-219 versus 11.8% for placebo, despite similar treatment-emergent adverse-event incidence; reasons for withdrawal and the forthcoming longer safety data warrant scrutiny [#8-K-2026-10-20].

WatchKey bullets

FDA discussion of bipolar-mania registrational design

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $28 (p=45%)

Target spread vs base: +50% / -46%

Scenario probabilities

Bull Target: $42 (p=30%)Base Target: $28 (p=45%)Bear Target: $15 (p=25%)

Commentary

The October 20 Phase 2 result is a substantive positive change from the April filing-monitoring baseline, consistent with the packet's positive deterministic prior. Recent headlines focus on the trial win, while the filed discontinuation figures temper the interpretation [#8-K-2026-10-20]. The packet does not establish a quantified post-release share-price reaction or dated analyst revisions; its target figure lacks a source count. The October 21 $25.06 anchor is a price level, not evidence of the reaction's size. No sufficient social, options, short-interest or employee-sentiment data were supplied.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Focal-onset-seizure extension safety data
Broader RAP-219 epilepsy development
Bipolar-mania Phase 3 initiation

Scenarios

Bull Target (Scenario probability)

$42 / p=30% prob

Base Target (Scenario probability)

$28 / p=45% prob

Bear Target (Scenario probability)

$15 / p=25% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
FDA discussion of bipolar-mania registrational design
After the Phase 2 trial met its primary endpoint by 3.1 YMRS points versus placebo at Week 3 (p=0.045), Rapport plans an FDA end-of-Phase-2 meeting in Q1 2027. Regulatory feedback on the proposed registrational design is more consequential than the topline result alone [#8-K-2026-10-20].
Prob 75.00% • Move 18.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Focal-onset-seizure extension safety data
2026-12-31
Initial data from the RAP-219 Phase 2a open-label long-term safety extension are expected in Q4 2026. Durability and tolerability matter while FOCUS 1 and FOCUS 2 Phase 3 trials enroll; the date and scope are company-stated, not guaranteed [#8-K-2026-10-20].
Prob 70% • Move 10% • Priced-in 45%

Long-term Catalysts

Months to a year

Broader RAP-219 epilepsy development
2027-06-30
Rapport expects to begin a Phase 3 primary generalized tonic-clonic seizure trial in H1 2027, alongside its enrolling focal-onset-seizure pivotal program. Execution could broaden RAP-219's opportunity, but both indications remain subject to clinical and regulatory risk [#8-K-2026-10-20].
Prob 60% • Move 16% • Priced-in 35%
Bipolar-mania Phase 3 initiation
2027-12-31
Rapport expects two pivotal bipolar-mania trials to begin in H2 2027, subject to development work and FDA feedback. The positive Phase 2 readout supports advancement but does not establish registrational efficacy [#8-K-2026-10-20].
Prob 55% • Move 22% • Priced-in 40%

Risks

FDA feedback could require changes to the proposed bipolar-mania registrational program or delay its planned H2 2027 start [#8-K-2026-10-20].
Multiple planned Phase 3 studies may raise R&D spending and operational complexity; the H2 2029 runway is a company expectation based on June 30, 2026 liquidity, not a financing guarantee [#8-K-2026-10-20].
Overall treatment discontinuation was 24.6% for RAP-219 versus 11.8% for placebo, despite similar treatment-emergent adverse-event incidence; reasons for withdrawal and the forthcoming longer safety data warrant scrutiny [#8-K-2026-10-20].
The bipolar-mania efficacy margin is modest and close to the conventional significance threshold; Phase 3 replication is uncertain [#8-K-2026-10-20].

Peers

Symbol	Summary
BCAX	Similar-sized development-stage biotech candidate, but not a direct neuroscience or indication peer; useful only as a rough financing and clinical-risk comparison.
KARD	Similar market capitalization makes it a rough small-biotech comparator, not a validated RAP-219 product or indication peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

BCAX

Similar-sized development-stage biotech candidate, but not a direct neuroscience or indication peer; useful only as a rough financing and clinical-risk comparison.

KARD

Similar market capitalization makes it a rough small-biotech comparator, not a validated RAP-219 product or indication peer.